Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is exhibiting promising results in preliminary clinical studies. Ongoing inquiry https://modernbookmarks.com/story21144780/retatrutide-emerging-investigations-and-possible-clinical-applications